Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.57 |
| ▸ | LPL | P06858 | 7/20 | 0.57 |
| ▸ | F11 | P03951 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.51 |
| ▸ | P4HB | P07237 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478572 | 0.86 | LIPG (0.57) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL18513174 | 0.85 | LIPG (0.56) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL514356 | 0.85 | F11 (0.60) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL902460 | 0.83 | LIPG (0.69) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL481948 | 0.82 | LIPG (0.53) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL30690785 | 0.82 | LIPG (0.53) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL16218374 | 0.82 | LIPG (0.53) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL19358832 | 0.81 | F11 (0.41) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL5200661 | 0.81 | LMNA (0.42) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL2151053 | 0.81 | LIPG (0.63) | LIPGLPLF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119055578-A | Intelligent glucose response type micro needle tube and preparation method and application thereof | 浙江大学 | 2024-12-03 | — | — | CN | claimed |
| CN-118121530-A | Three-section type microneedle patch for long-acting blood sugar self-regulation and control and preparation method thereof | 浙江大学 | 2024-06-04 | — | — | CN | claimed |
| EP-4727537-A2 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | Adaxion Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250213560-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | BNH RESEARCH CO., LTD. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20250147039-A1 | Compounds for complexation of rare earth elements and/or s-, p-, d- block metals, their coordination compounds, peptide conjugates, method of their preparation and use thereof | Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) | 2025-05-08 | — | — | US | disclosed |
| CN-119638639-A | Biaryl compound with anti-cell necrotic apoptosis activity, derivative and application thereof | 中国药科大学 | 2025-03-18 | — | — | CN | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | ADAXION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2006030032-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | BERTHEL STEVEN JOSEPH (US) | 2004-11-25 | — | — | US | disclosed |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235872-A1 | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | PTPN5, PPP5C, PTP4A2 | LIPG 1632/4885LPL 2216/4885F11 4384/4885 |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | MMP3, MMP13, MMP10 | LIPG 902/4885LPL 1416/4885F11 334/4885 |
| US-20250213560-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | PNMT, BDNF, NLN | LIPG 4871/4885LPL 4481/4885F11 4123/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | LIPG 4176/4885LPL 4794/4885F11 4414/4885 |
| US-20250064941-A1 | SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF | SIGLEC7, SIGLEC9, CD2BP2 | LIPG 1065/4885LPL 1848/4885F11 914/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | LIPG 4786/4885LPL 4774/4885F11 619/4885 |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | LIPG 1861/4885LPL 1106/4885F11 796/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | LIPG 3220/4885LPL 4579/4885F11 4354/4885 |
| US-20250147039-A1 | Compounds for complexation of rare earth elements and/or s-, p-, d- block metals, their coordination compounds, peptide conjugates, method of their preparation and use thereof | SCLY, CD79B, CSTB | LIPG 4548/4885LPL 4698/4885F11 98/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | LIPG 173/4885LPL 99/4885F11 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.